During the 13th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2020) scheduled to take place in Madrid, Spain, 19-22 February 2020, Adocia is pleased to present the E-Poster: “ADO09, A CO-FORMULATION OF THE AMYLIN-ANALOG PRAMLINTIDE AND THE A21G HUMAN INSULIN ANALOG, LOWERS POSTPRANDIAL BLOOD GLUCOSE VERSUS INSULIN LISPRO IN TYPE 1 DIABETES
Gerard Soula, ADOCIA CEO, and Steve Daly, ADOCIA US General Manager, attended the #EastWestCEOConference last January 11th and 12th: an introduction to #JPMorganHealthcareConference which is beginning January 13th until January 16th in San Francisco!
At the occasion of World Diabetes Day, Thursday November 14th, 2019 Adocia comes to meet you to make you discover its promising portfolio and answer your questions. Biotech Agora’s mission is to introduce investors to highly innovative companies in the field of Life Sciences, such as Adocia. Adocia’s Executive team will welcome you on November 14
A success for the second Edition of the French Forum Lyon Pôle Bourse which was held last September 25th, 2019 in Lyon! This Forum focuses on one to one meetings between investors and regional companies. During this event, 84 professional investors met the 36 listed companies. To watch the video about Adocia by Olivier Soula, Deputy
Dear investors, Meet Adocia at the second Forum “Lyon Pole Bourse” which will held in Lyon next September 25th! This Forum is focusing on “one to one” meetings between investors and regional companies. To register: www.forum-lyon-pole-bourse.com
Adocia announces an oral presentation at the 55th European Association for the Study of Diabetes EASD congress, being held September 16-20, 2019 in Barcelona, Spain. This Abstract will cover its ADO09 (pramlintide insulin) product: Oral Presentation #109: ADO09, a co-formulation of the amylin-analog pramlintide and the A21G human insulin analog, lowers postprandial blood glucose versus
Dear all, Following Adocia’s Press Release distributed today regarding the decision in the Second Phase of the Arbitration with Eli Lilly, Adocia will hold a conference call to answer shareholders’ questions today, August 23rd, 2019. The following members of Adocia’s leadership team will conduct the call: Gérard Soula, President and CEO Olivier Soula, R&D Director
Last June 9th and 10th, Adocia presented two abstracts during the 79th Scientific Sessions organized by the American Diabetes Association® this year at the Moscone Center in San Francisco (USA)   Oral  Presentation #150-OR: Biochaperone Pramlintide Insulin (BCPramIns), A New Co-formulation Of Pramlintide (pram) And Human Insulin (ins), Improves Post-prandial Blood Glucose (BG) Versus Both
Adocia will be presenting two abstracts at the 79th Scientific Sessions of the American Diabetes Association® #ADA2019. Join us on June 9th and June 10th for these presentations in San Francisco – USA! Details of the accepted abstracts are presented below: Oral Presentation #150-OR: Biochaperone Pramlintide Insulin (BCPramIns), A New Co-formulation Of Pramlintide (pram) And Human